Interpace Biosciences, Inc.
IDXG
$1.14
-$0.03-2.56%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 41.63% | 308.47% | 1,078.29% | 33.33% | 230.56% |
| Total Depreciation and Amortization | 13.44% | -46.31% | -66.78% | -67.81% | -85.65% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -100.00% |
| Total Other Non-Cash Items | -42.63% | 13.30% | -98.07% | -37.11% | -70.46% |
| Change in Net Operating Assets | -42.44% | -83.32% | -20.65% | -1,149.35% | -2.01% |
| Cash from Operations | 3.86% | 91.49% | 241.61% | -105.12% | 513.04% |
| Capital Expenditure | 9.15% | -243.42% | -77.48% | 56.92% | 27.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Investing | 9.15% | -250.00% | 13.60% | 56.92% | 87.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 0.00% | -185.71% | -100.00% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -43.75% | -- | -- | -- | 70.37% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 93.56% | -- | -- | -- | -- |
| Cash from Financing | 32.58% | 0.00% | -185.71% | -100.00% | -2,288.68% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 57.50% | 300.00% | -53.38% | -189.32% | -3.58% |